Adam Scott Feldman, MD, MPH

Looking to the future treatment landscape in prostate cancer, the panel provides closing thoughts on the trajectory of the utilization of PSMA-PET imaging and the unmet needs it might address.

Experts on prostate cancer discuss the benefits to multidisciplinary care as it pertains to PSMA-PET imaging.

Prostate cancer specialists discuss challenges associated with imaging in clinical practice.

A panel of experts on prostate cancer share strategies for monitoring patients and discuss whether to use PSMA to monitor treatment response.

Experts on prostate cancer discuss the ideal timing and frequency of PSMA-PET imaging and the role of different PSMA-PET agents.

Focusing on active surveillance of patients with prostate cancer, discussion centers around the role of PSMA-PET imaging and the implications of negative scans.

The panel discusses how PSMA-PET imaging informs treatment decisions for patients with prostate cancer.

Steven Finkelstein, MD, FACRO, discusses PSMA-PET imaging practices for patients experiencing biochemical recurrence.

Experts on prostate cancer offer clinical insights on identifying the appropriate patients for PSMA-PET imaging.

The panel discusses the role of PSMA-PET imaging in prostate cancer and highlights different PSMA agents.

A panel of experts on prostate cancer provide an overview of conventional imaging modalities that have been used in the initial staging and management of prostate cancer and discuss the role of PSMA-PET imaging.